Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about EIKN, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Resiquimod Sulfate (BDB001) | Advanced Melanoma | Phase 2/3 · NCT06697301 | Recruiting |
| Nab-paclitaxel | Non Small Cell Lung Cancer (Squamous or Non Squamous) | Phase 2/3 · NCT07365319 | Recruiting |
| WRN Inhibitor EIK1005 | Advanced Solid Tumors | Phase 1/2 · NCT07262619 | Recruiting |
| PARP1 Inhibitor IMP1734 | Advanced Solid Tumor | Phase 1/2 · NCT06253130 | Recruiting |
| PARP1 Inhibitor EIK1004 | Advanced Solid Tumors | Phase 1/2 · NCT06907043 | Recruiting |
| Toll-like Receptor 7/8 Agonist BDB018 | Tumor, Solid | Phase 1 · NCT04840394 | Completed |
Also used in these trials (approved or third-party drugs, not EIKN's own candidates): Pemetrexed Disodium, Pembrolizumab, Paclitaxel, Carboplatin, Atezolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
EIKN holds $461.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $67.1M/quarter from operations, an estimated runway of 20.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 11 · Low
Based on our current operating plan, we estimate that our existing cash, cash equivalents, and marketable securities as of the date of this Quarterly Report will be sufficient to fund our operating expenses and capital expenditures into the first quarter of 2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EIKN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Tim Kutzkey | 5%+ holder (13D) | 6,353,712 | 11.73% | 2026-02-06 |
| Column Group IV GP, LP 10% owner |
Insider | 5,869,343 | 10.84% | 2026-09-03 |
| FMR LLC | Institution (13G, 5%+) | 5,520,152 | 10.19% | 2026-09-30 |
| James B. Tananbaum | 5%+ holder (13G) | 4,148,519 | 7.66% | 2026-02-04 |
| BlackRock Portfolio Management LLC | Institution (13G, 5%+) | 3,002,737 | 5.54% | 2026-03-31 |
| Innovation Endeavors III LP | 5%+ holder (13G) | 2,723,226 | 5.03% | 2026-03-31 |
| Lux Venture Partners V, LLC 10% owner |
Insider | 2,294,653 | 4.24% | 2026-02-04 |
| Josh Wolfe Director, 10% owner Includes shares also reported by Lux Venture Partners V, LLC, counted once |
Insider | 2,294,653 | 4.24% | 2026-02-04 |
| Foresite Capital Management IV, LLC 10% owner · +34,185 options |
Insider | 1,318,983 | 2.44% | 2026-02-04 |
| Roger M Perlmutter Chief Executive Officer and Director, Di · +268,176 options |
Insider | 284,857 | 0.53% | 2026-02-06 |
| Kenneth C Frazier Director · +25,873 options |
Insider | 111,111 | 0.21% | 2026-02-04 |
| Alfred Lloyd Jr. Bowie Chief Financial Officer · +67,044 options |
Insider | 51,572 | 0.10% | 2026-02-04 |
Share count 54,165,030 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EIKN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →